Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completed

Domperidone and the Risk of Serious Adverse Events

NCT07098078
completedphase_2

Effect of Domperidone on QT Interval in Premature Infants

NCT00238056
terminatedphase_2

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

NCT00305331

Clinical Trials (3)

Showing 3 of 3 trials
NCT07098078

Domperidone and the Risk of Serious Adverse Events

Completed
NCT00238056Phase 2

Effect of Domperidone on QT Interval in Premature Infants

Completed
NCT00305331Phase 2

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3